Transcription of Key Potential Drug Launches
{{id}} {{{paragraph}}}
Example: bachelor of science
Key Potential Drug Launches
As a supplement to our well-known quarterly outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2022. These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Potential Drug Launches in 2022 The information in this presentation, including likelihood of approval (LOA) ratings and upcoming catalysts, is up to date as of April 2021.
Cardiomyopathy - Hypertrophic Mavacamten is an is an allosteric inhibitor of myosin that reduces heart contractility for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In that condition, the thickened and stiff walls of the heart lead to obstruction of outflow, and paradoxically, the degree of
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: